The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma-Reference-Cited by-同舟云学术

The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma

Published:2015-06-23 Issue:27 Volume:6 Page:23609-23630
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Fionda Cinzia¹,Abruzzese Maria Pia¹,Zingoni Alessandra¹,Cecere Francesca¹,Vulpis Elisabetta¹,Peruzzi Giovanna²,Soriani Alessandra¹,Molfetta Rosa¹,Paolini Rossella¹,Ricciardi Maria Rosaria³,Petrucci Maria Teresa³,Santoni Angela¹⁴,Cippitelli Marco¹

Affiliation:

1. Department of Molecular Medicine, Istituto Pasteur-Fondazione Cenci Bolognetti, Sapienza University of Rome, Rome, Italy

2. Istituto Italiano di Tecnologia, CLNS@Sapienza, Sapienza University of Rome, Rome, Italy

3. Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Rome, Italy

4. Istituto Mediterraneo di Neuroscienze Neuromed, Pozzilli, Italy

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide;Expert Review of Hematology;2024-07-27

2. Gene expression profiling in white blood cells reveals new insights into the molecular mechanisms of thalidomide in children with inflammatory bowel disease;Biomedicine & Pharmacotherapy;2023-08

3. Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond;Frontiers in Immunology;2023-07-18

4. Dissecting molecular mechanisms of immune microenvironment dysfunction in multiple myeloma and precursor conditions;Journal of Cancer Metastasis and Treatment;2023

5. IKZF3 modulates cerebral ischemia/reperfusion injury by inhibiting neuroinflammation;International Immunopharmacology;2023-01